We are pleased to report that our CEO, Alexander Seyf, featured in the latest Scrip Asks article, “What Does 2026 Hold For Biopharma? Part 5: AI And Operational Excellence“.

The article explores the transformative yet cautious integration of Artificial Intelligence (AI) within the Cell and Gene Therapy (CGT) sector and examines how AI is moving from a novelty to a core operational tool while highlighting the significant risks regarding data privacy, bias, and the potential for “hallucinations” in scientific research.

Within the article, Alexander discusses how the Biopharma sector is moving beyond AI pilots toward verifiable operational excellencein manufacturing as companies are eliminating the quality review bottleneck and streamlining QA narratives. This shift focuses on “time-to-release” efficiency—lowering costs and accelerating the delivery of life-saving cell and gene therapies to patients globally.

For more perspective on this topic, click here.